keyword
https://read.qxmd.com/read/38529688/combination-of-egfr-tki-and-chemotherapy-versus-egfr-tki-monotherapy-as-neoadjuvant-treatment-of-stage-iii-n2-egfr-mutant-non-small-cell-lung-cancer
#21
JOURNAL ARTICLE
Yingqi Xu, Hao Ji, Yidan Zhang, Liwen Xiong, Baohui Han, Hua Zhong, Jianlin Xu, Runbo Zhong
BACKGROUND: The efficacy of neoadjuvant treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) monotherapy in patients with stage III-N2 EGFR-mutant remains unsatisfactory. This study explored the potential benefits of combining first-generation EGFR-TKI with chemotherapy as a neoadjuvant treatment for patients with stage III-N2 EGFR-mutant non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: The medical records of patients with III-N2 EGFR-mutant NSCLC who received neoadjuvant therapy with EGFR-TKI at Shanghai Chest Hospital from October 2011 to October 2022 were retrospectively reviewed...
March 25, 2024: Oncologist
https://read.qxmd.com/read/38529385/prediction-of-pathologic-complete-response-to-neoadjuvant-chemoradiation-in-locally-advanced-rectal-cancer
#22
JOURNAL ARTICLE
Xiaoling Zhong, Guohua Zeng, Lixiang Zhang, Shuyuan You, Yuxiang Fu, Wan He, Guixiang Liao
PURPOSE: To investigate the predictive factors of pathologic complete response (pCR) in locally advanced rectal cancer (LARC) patients who had been treated with neoadjuvant chemoradiation (nCRT). METHODS AND MATERIALS: For this retrospective study, 53 LARC patients (37 males and 16 females; age range 25 to 79 years) were selected. Clinical characteristics, baseline mrTNM staging, MR gross tumor volumes (GTV), and pCR were evaluated. The diagnostic accuracy of GTV for predicting pCR was calculated...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38527730/controversia-en-la-estadificaci%C3%A3-n-inicial-ganglionar-en-el-ca-de-recto-%C3%A2-rm-o-pet-tc
#23
JOURNAL ARTICLE
Elena López Llobet, Mónica Coronado Poggio, Carmen Lancha Hernández, Carmen Martín Hervás, Daniela Travaglio Morales, Doménico Monachello Araujo, Sonia Rodado Marina, Luís Domínguez Gadea
OBJECTIVE: To compare the usefulness of MRI and PET/CT in nodal staging (N) of patients with locally advanced rectal cancer (LARC). MATERIAL AND METHODS: Retrospective study of patients with LARC, who completed their initial staging with PET/CT, between January-20 and March-23. Regional nodes were assessed, and N was determined using both techniques according to TNM criteria. Concordance between MRI and PET/CT was analyzed. The accuracy of both techniques was calculated for those patients who underwent direct surgery...
March 23, 2024: Revista española de medicina nuclear e imagen molecular
https://read.qxmd.com/read/38527495/long-term-multimodal-recording-reveals-epigenetic-adaptation-routes-in-dormant-breast-cancer-cells
#24
JOURNAL ARTICLE
Dalia Rosano, Emre Sofyali, Heena Dhiman, Chiara Ghirardi, Diana Ivanoiu, Timon Heide, Andrea Vingiani, Alessia Bertolotti, Giancarlo Pruneri, Eleonora Canale, Hannah F Dewhurst, Debjani Saha, Neil Slaven, Iros Barozzi, Tong Li, Grigory Zemlyanskiy, Henry Phillips, Chela James, Balázs Győrffy, Claire Lynn, George D Cresswell, Farah Rehman, Roberta Noberini, Tiziana Bonaldi, Andrea Sottoriva, Luca Magnani
UNLABELLED: Patients with estrogen receptor-positive breast cancer receive adjuvant endocrine therapies (ET) that delay relapse by targeting clinically undetectable micrometastatic deposits. Yet, up to 50% of patients relapse even decades after surgery through unknown mechanisms likely involving dormancy. To investigate genetic and transcriptional changes underlying tumor awakening, we analyzed late relapse patients and longitudinally profiled a rare cohort treated with long-term neoadjuvant ETs until progression...
March 21, 2024: Cancer Discovery
https://read.qxmd.com/read/38527258/treatment-of-stage-iii-resectable-melanoma-adjuvant-and-neoadjuvant-approaches
#25
JOURNAL ARTICLE
Ahmad A Tarhini, Ella Castellano, Islam Eljilany
Patients with stage III resectable melanoma carry a high risk of melanoma recurrence that ranges from approximately 40% to 90% at 5 years following surgical management alone. Postoperative systemic adjuvant therapy targets residual micrometastatic disease that could be the source of future recurrence and death from melanoma. Randomized phase III adjuvant trials reported significant improvements in overall survival with high-dose interferon α in 2 of 3 studies (compared with observation and GMK ganglioside vaccine) and with anti-cytotoxic T-lymphocyte antigen 4 ipilimumab at 10 mg/kg compared with placebo and ipilimumab 3 mg/kg compared with high-dose interferon α...
March 2024: Cancer Journal
https://read.qxmd.com/read/38527247/pyrotinib-and-trastuzumab-plus-chemotherapy-serve-as-an-acceptable-neoadjuvant-regimen-exhibiting-good-efficacy-and-tolerance-in-her2-positive-breast-cancer-patients
#26
JOURNAL ARTICLE
Yibo Chen, Tianyi Zhang, Rui Zhang, Xuchen Cao
Objective: Pyrotinib, a new irreversible dual pan-human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase inhibitor blocking EGFR and HER2, has achieved a promising efficacy for advanced HER2-positive (HER2+ ) breast cancer. This study intended to further investigate the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2+ breast cancer treatment. Methods: Thirty-eight HER2+ breast cancer patients who received neoadjuvant pyrotinib and trastuzumab plus chemotherapy (docetaxel and carboplatin) were retrospectively reviewed...
March 25, 2024: Cancer Biotherapy & Radiopharmaceuticals
https://read.qxmd.com/read/38525931/laparoscopic-or-open-abdominal-surgery-with-thoracotomy-for-patients-with-oesophageal-cancer-romio-randomized-clinical-trial
#27
RANDOMIZED CONTROLLED TRIAL
(no author information available yet)
OBJECTIVE: This study investigated if hybrid oesophagectomy with minimally invasive gastric mobilization and thoracotomy enabled faster recovery than open surgery. METHODS: In eight UK centres, this pragmatic RCT recruited patients for oesophagectomy to treat localized cancer. Participants were randomly allocated to hybrid or open surgery, stratified by centre and receipt of neoadjuvant treatment. Large dressings aimed to mask patients to their allocation for six days post-surgery...
March 2, 2024: British Journal of Surgery
https://read.qxmd.com/read/38525372/the-prognostic-value-of-serum-sialic-acid-in-patients-with-nasopharyngeal-carcinoma-a-propensity-score-matching-study
#28
JOURNAL ARTICLE
Zetan Chen, Gang Wu, Xiangying Lin, Xiaopeng Huang, Shuai Zhang, Kaihua Chen, Zhongguo Liang, Xiaodong Zhu
PURPOSE: Elevated serum sialic acid (SA) is one of the indicators of poor prognosis in various malignant tumors. This study intends to determine the relationship between serum SA levels and survival prognosis in nasopharyngeal carcinoma (NPC). PATIENTS AND METHODS: From 2014 to 2016, NPC patients with no distance metastasis undergoing intensity-modulated radiotherapy (IMRT) were retrospectively analyzed. The serum SA levels before initial treatment were measured, and an optimal cut-off level was determined by X-tile software...
2024: Cancer Management and Research
https://read.qxmd.com/read/38524658/significant-reduction-in-burden-of-metastatic-disease-by-intermittent-docetaxel-therapy-in-a-patient-with-castration-resistant-prostate-cancer
#29
JOURNAL ARTICLE
Takahiro Kirisawa, Eijiro Nakamura, Tomoya Okuno, Hiroki Hagimoto, Ayumu Matsuda, Yasuo Shinoda, Motokiyo Komiyama, Hiroyuki Fujimoto, Yoshiyuki Matsui
Intermittent docetaxel therapy (IDT) is rarely used nowadays as a treatment option for men with metastatic castration-resistant prostate cancer (mCRPC) because of the widespread availability of androgen receptor axis-targeted therapy, which is less toxic. Therefore, there is limited information available on whether IDT has a clinical benefit in the treatment of men with mCRPC. This report describes the case of a 66-year-old man with a diagnosis of cT2N1M0 prostate cancer who underwent neoadjuvant combined androgen blockade and whole-pelvis radiation therapy...
April 2024: International cancer conference journal
https://read.qxmd.com/read/38524656/spot-scanning-proton-therapy-for-unresectable-bulky-retroperitoneal-dedifferentiated-liposarcoma-a-case-report
#30
JOURNAL ARTICLE
Koichiro Nakajima, Hiromitsu Iwata, Shuo Sudo, Toshiyuki Toshito, Kensuke Hayashi, Masaki Sunagawa, Yukihiro Yokoyama, Hiroyuki Ogino
The development of effective treatment strategies for unresectable retroperitoneal sarcoma is desirable. Herein, we suggest that definitive proton therapy (PT) could be a promising treatment option, regardless of the large size of the tumor. A 52-year-old man presented with a discomfort of the lower abdomen. Computed tomography revealed a retroperitoneal tumor, measuring over 20 cm in the largest dimensions, which was surrounded by the gastrointestinal (GI) tract. Biopsy revealed dedifferentiated liposarcoma...
April 2024: International cancer conference journal
https://read.qxmd.com/read/38524652/primary-signet-ring-cell-carcinoma-of-the-bladder-treated-with-laparoscopic-radical-cystectomy-a-case-report
#31
JOURNAL ARTICLE
Yuta Mukae, Kojiro Ohba, Kyohei Araki, Yuichiro Nakamura, Hiromi Nakanishi, Takuji Yasuda, Kensuke Mitsunari, Tomohiro Matsuo, Yasushi Mochizuki, Junji Irie, Ryoichi Imamura
Primary bladder adenocarcinomas comprise 0.5-2% of all epithelial bladder neoplasms. Of these, primary signet-ring cell carcinoma of the bladder is particularly rare, accounting for 0.24% of all bladder malignancies. This tumor is frequently diagnosed at an advanced stage and has a poor prognosis. No standard treatment has yet been established. We here report a patient in whom laparoscopic cystectomy following neoadjuvant chemotherapy was effective. Our patient was a 69-year-old man who had had microscopic hematuria, undergone transurethral resection of a mass in the bladder, and been diagnosed pathologically with a primary signet-ring cell carcinoma of the bladder...
April 2024: International cancer conference journal
https://read.qxmd.com/read/38524644/complete-reduction-surgery-of-a-huge-recurrent-adult-granulosa-cell-tumor-after-neoadjuvant-chemotherapy
#32
JOURNAL ARTICLE
Hiroha Tokui, Hideaki Yahata, Yasuhiro Okabe, Naomi Magarifuchi, Shoji Maenohara, Kazuhisa Hachisuga, Hiroshi Tomonobe, Keisuke Kodama, Hiroshi Yagi, Masafumi Yasunaga, Ichiro Onoyama, Kazuo Asanoma, Yoshinao Oda, Masafumi Nakamura, Kiyoko Kato
Adult granulosa cell tumors are rare, accounting for only 3-5% of all ovarian tumors. Adult granulosa cell tumors have late recurrences, for which complete resection is an effective option. We report a patient who underwent complete resection of a huge recurrent adult granulosa cell tumor after neoadjuvant chemotherapy. A 72-year-old woman underwent primary surgery for an adult granulosa cell tumor 19 years earlier. A huge recurrent tumor, 11 × 10 cm in size, was noted to elevate the hepatic hilum, inferior vena cava, and right renal vein...
April 2024: International cancer conference journal
https://read.qxmd.com/read/38524592/differential-clinical-outcomes-after-3-versus-5-years-in-a-comparison-of-preoperative-chemotherapy-with-and-without-radiotherapy-in-locally-advanced-rectal-cancer-a-national-cohort-propensity-score-matched-study
#33
JOURNAL ARTICLE
Yuanxin Zhang, Rui Luo, Jingqi Peng, Zichuan He, Delin Tan, Xueping Liu, Hui Wang, Huaiming Wang
BACKGROUND: Preoperative chemotherapy alone might be a good alternative to preoperative chemoradiotherapy for patients with locally advanced rectal cancer, yet long-term real-world data from the same cohort are lacking. METHODS: Patients diagnosed with stage II-III rectal adenocarcinoma from 2011 to 2015 were randomly sampled from the SEER-Plus database to evaluate the superiority of preoperative chemoradiotherapy versus preoperative chemotherapy alone. FINDINGS: A total of 1314 eligible patients were enrolled, with a median follow-up of 74...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38524569/txnrd1-as-a-prognosticator-for-recurrence-metastasis-and-response-to-neoadjuvant-chemotherapy-and-radiotherapy-in-breast-cancer-patients
#34
JOURNAL ARTICLE
Raghavendra S Patwardhan, Archita Rai, Deepak Sharma, Santosh K Sandur, Sejal Patwardhan
Thioredoxin reductase 1 (Txnrd1) is known to have prognostic significance in a subset of breast cancer patients. Despite the pivotal role of Txnrd1 in regulating several cellular and physiological processes in cancer progression and metastasis, its clinical significance is largely unrecognized. Here, we undertook a retrospective comprehensive meta-analysis of 13,322 breast cancer patients from 43 independent cohorts to assess prognostic and predictive roles of Txnrd1. We observed that Txnrd1 has a positive correlation with tumor grade and size and it is over-expressed in higher-grade and larger tumors...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38524124/neoadjuvant-therapy-with-chemotherapy-and-immune-checkpoint-inhibitor-for-laryngeal-function-preservation-in-locally-advanced-hypopharyngeal-cancer
#35
JOURNAL ARTICLE
San-Gang Wu, Run-Jie Wang, Yi Zhou, Xian-Yang Luo
PURPOSE: To evaluate the efficacy and laryngeal function preservation of neoadjuvant treatment with chemotherapy and immune checkpoint inhibitor for locally advanced hypopharyngeal cancer (LAHPC). METHODS: We retrospectively collected LAHPC patients who were diagnosed between February 2022 and June 2023. The patients received a combination of chemotherapy and immune checkpoint inhibitors as the neoadjuvant therapy. The response to treatment, laryngeal function preservation rate, and short-term survival were assessed...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38523553/nomogram-for-predicting-pathological-response-to-neoadjuvant-treatment-in-patients-with-locally-advanced-gastric-cancer-data-from-a-phase-iii-clinical-trial
#36
JOURNAL ARTICLE
Han Shao, Nai Li, Yi-Hong Ling, Ji-Jin Wang, Yi Fang, Ming Jing, Zhi-Wei Zhou, Yu-Jing Zhang
PURPOSE: This study aimed to establish a nomogram using routinely available clinicopathological parameters to predict the pathological response in patients with locally advanced gastric cancer (LAGC) undergoing neoadjuvant treatment. MATERIALS AND METHODS: We conducted this study based on the ongoing Neo-CRAG trial, a prospective study focused on preoperative treatment in patients with LAGC. A total of 221 patients who underwent surgery following neoadjuvant chemotherapy (nCT) or neoadjuvant chemoradiotherapy (nCRT) at Sun Yat-sen University Cancer Center between June 2013 and July 2022 were included in the analysis...
March 2024: Cancer Medicine
https://read.qxmd.com/read/38523397/comparison-of-clinical-characteristics-between-acosog-z0011-eligible-cohort-and-sentinel-lymph-node-positive-breast-cancer-patients-in-hong-kong
#37
JOURNAL ARTICLE
V Man, A Kwong
INTRODUCTION: The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial resulted in de-escalation of axillary surgery among early-stage breast cancer patients with low-volume sentinel lymph node (SLN) disease undergoing breast-conserving surgery and radiation therapy. Nevertheless, the mastectomy rate in the Chinese population remains high. This study compared the clinical characteristics of the ACOSOG Z0011-eligible cohort with SLN-positive breast cancer patients in Hong Kong...
March 25, 2024: Hong Kong Medical Journal
https://read.qxmd.com/read/38523225/implementation-of-the-targeted-axillary-dissection-procedure-in-clinically-node-positive-breast-cancer-a-retrospective-analysis
#38
JOURNAL ARTICLE
Joni J Nijveldt, Kiran K Rajan, Karina Boersma, Eva M Noorda, Jose van der Starre-Gaal, Miranda van 't Veer-Ten Kate, Ellen M A Roeloffzen, Brian N Vendel, Maarten A Beek, Anne Brecht Francken
BACKGROUND: The targeted axillary dissection (TAD) procedure is used in clinically positive lymph node (cN+) breast cancer to assess whether pathological complete response (pCR) is achieved after neoadjuvant systemic therapy (NST) to decide on de-escalation of axillary lymph node dissection (ALND). In this study, we review the implementation of the TAD procedure in a large regional breast cancer center. METHODS: All TAD procedures between 2016 and 2022 were reviewed...
March 24, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38522889/endoscopic-resection-of-residual-rectal-neoplasia-after-definitive-chemoradiotherapy-for-rectal-cancer
#39
REVIEW
Robert Klimkowski, Jakub Krzyzkowiak, Nastazja Dagny Pilonis, Krzysztof Bujko, Michal F Kaminski
The conventional approach to treating locally advanced rectal cancer, commonly defined as cT3 or cT4 primary tumors or with nodal metastases, involves chemoradiation (CRT) followed by surgical resection. There is a growing recognition of the potential for nonsurgical management following CRT or total neoadjuvant therapy (TNT), which allows for organ preservation. "Watch and wait" strategy may be considered if complete clinical response is achieved. In cases when adenoma or superficial cancer is present, a novel approach known as "salvage endoscopic resection of the residual disease" is emerging as a viable nonsurgical option for carefully selected patients...
February 2024: Best Practice & Research. Clinical Gastroenterology
https://read.qxmd.com/read/38522883/endoscopic-resection-for-residual-oesophageal-neoplasia-after-definitive-chemoradiotherapy
#40
REVIEW
Judith Honing, Arjun D Koch, Peter D Siersema, Manon Spaander
Definitive chemoradiation is the recommended treatment for locally advanced, irresectable oesophageal cancer and a valid alternative to neoadjuvant chemoradiotherapy (CRT) with surgery in oesophageal squamous cell cancer (OSCC) patients. In case of locoregional recurrence, salvage treatment can be considered in fit and resectable patients. Salvage surgery is a valid option but associated with significant morbidity. Therefore, for tumors confined to the mucosa or submucosal layers endoscopic resection is a good and less-invasive alternative...
February 2024: Best Practice & Research. Clinical Gastroenterology
keyword
keyword
50051
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.